Rare Diseases >> Abstract Details   Binding Domains from Plasmodium vivax and Plasmodium falciparum Erythrocyte Binding Proteins Description of Invention: Despite considerable research efforts worldwide it has not been possible to design an effective vaccine against malaria. The present invention provides the basis for an effective vaccine against the blood state of malaria infections. This invention relates to the identification of functional domains of Plasmodium proteins which play a role in erythrocyte binding and invasion. The inventors have identified the erythrocyte binding domains of the sialic acid binding protein (SABP) of P. falciparum and the Duffy antigen binding protein (DABP) of P. vivax. The erythrocyte binding domains can be used as vaccines to induce immune responses which block erythrocyte binding and invasion by P. falciparum and P. vivax merozoites. Inventors: Kim L. Sim (NIAID) Chetan Chitnis (NIAID) Louis H. Miller (NIAID) Patent Status: DHHS Reference No. E-133-1993/0 -- U.S. Patent No. 5,849,306 issued 15 Dec 1998 U.S. Patent No. 6,392,026 issued 21 May 2002 U.S. Patent No. 6,962,987 issued 08 Nov 2005 DHHS Reference No. E-133-1993/1 -- U.S. Patent No. 5,993,827 issued 30 Nov 1999 Portfolios: Infectious Diseases Infectious Diseases -Vaccines-Parasitic Infectious Diseases -Vaccines For Additional Information Please Contact: RC Tang JD, LLM NIH Office of Technology Transfer 6011 Executive Blvd, Suite 325 Rockville, MD 20852-3804 Phone: 301/435-5031 Email: tangrc@mail.nih.gov Fax: 301/402-0220 Web Ref: 1183 Last Updated On: 2/94